Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-trial access cohort of bumetanide for neurodevelopmental disorders
NL-OMON55058Completed
- Sponsor
- Vrije University Medical Center
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of bumetanide in Neurodevelopmental disorder (NDD), Autism Spectrum Disorder (ASD), attention deficit hyperactivity disorder (ADHD) and 4 more, sponsored by Vrije University Medical Center. Primary endpoints: PROMIS Physical stress experiences, PROMIS Psychological stress experience and 8 more. Started Dec 2020; status: completed.
02
Drugs
bumetanide
03
Conditions
Neurodevelopmental disorder (NDD)Autism Spectrum Disorder (ASD)attention deficit hyperactivity disorder (ADHD)intellectual disability (ID)learning disorder
Beyond the preview
Go deeper on NL-OMON55058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55058.